Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineReferences
- Cancer in kidney transplant recipients.Nat Rev Nephrol. 2018; 14: 508-520
- Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network.Clin Kidney J. 2018; 11: 315-329
- Patient survival after the diagnosis of cancer in renal transplant recipients: a nested case-control study.Transplantation. 2010; 90: 1542-1546
- Cumulative incidence of cancer after solid organ transplantation.Cancer. 2013; 119: 2300-2308
- Spectrum of cancer risk among US solid organ transplant recipients.JAMA. 2011; 306: 1891-1901
- The role of hypoxia-inducible factors in organ donation and transplantation: the current perspective and future opportunities.Am J Transplant. 2014; 14: 1481-1487
- Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.Sci Rep. 2017; 7: 5900
- Novel approaches to preventing ischemia-reperfusion injury during liver transplantation.Transplant Proc. 2013; 45: 2083-2092
- Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer.Cancer Res. 2008; 68: 5689-5698
- Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?.Int J Cancer. 2016; 138: 281-292
- Belatacept in solid organ transplant: review of current literature across transplant types.Transplantation. 2018; 102: 1440-1452
- Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.Transpl Int. 2008; 21: 207-217
- Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells.Cancer Res. 2009; 69: 8902-8909
- Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression.J Am Soc Nephrol. 2008; 19: 2437-2446
- Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40.PLoS One. 2011; 6: e23919
- Cyclosporine induces cancer progression by a cell-autonomous mechanism.Nature. 1999; 397: 530-534
- Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients.Am J Transplant. 2008; 8: 2205-2211
- Viral inhibitor of apoptosis vFLIP/K13 protects endothelial cells against superoxide-induced cell death.J Virol. 2009; 83: 598-611
- Kaposi sarcoma-associated herpesvirus g protein-coupled receptor enhances endothelial cell survival in part by upregulation of bcl-2.Ochsner J. 2013; 13: 66-75
- The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor: lessons on dysregulated angiogenesis from a viral oncogene.J Cell Biochem. 2010; 110: 1-9
- Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites.Cancers (Basel). 2016; 8 ([pii:E95])
- The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma.Clin Liver Dis. 2011; 15 (vii–x): 261-279
- Cyclosporine A inhibits the T-bet-dependent antitumor response of CD8(+) T cells.Am J Transplant. 2016; 16: 1139-1147
- Differential effects of immunosuppressive drugs on T-cell motility.Am J Transplant. 2006; 6: 2871-2883
Article info
Publication history
Footnotes
Disclosure Statement: This work is supported by National Institute of Health Grants R01 CA222355 and R01 CA193675 (to S.P.)